Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
17 Aug 2018 Blood-based Tumour Mutational Burden Assay Predicts Clinical Benefit in NSCLC Patients Treated with Atezolizumab Lung and other thoracic tumours - Translational research - Cancer Immunology and Immunotherapy
16 Aug 2018 EMA Recommends Granting a Marketing Authorisation for Generic Lenalidomide Haematologic malignancies - Anticancer agents & Biologic therapy
14 Aug 2018 EMA Refuses a Change to the Marketing Authorisations for Nivolumab and Ipilimumab Genitourinary cancers - Cancer Immunology and Immunotherapy
13 Aug 2018 FDA Approves Mogamulizumab-kpkc for Mycosis Fungoides or Sézary Syndrome Haematologic malignancies - Cancer Immunology and Immunotherapy
10 Aug 2018 EMA Recommends Granting a Marketing Authorisation for Generic Gefitinib Lung and other thoracic tumours - Personalised medicine - Anticancer agents & Biologic therapy
09 Aug 2018 EMA Recommends Extension of Indications for Daratumumab Haematologic malignancies - Anticancer agents & Biologic therapy
08 Aug 2018 EMA Recommends Extension of Indications for Blinatumomab Haematologic malignancies - Cancer Immunology and Immunotherapy
07 Aug 2018 EMA Recommends Extension of Indications for Dabrafenib and Trametinib Melanoma and other skin tumours - Anticancer agents & Biologic therapy
06 Aug 2018 EMA Recommends Extension of Indications for Pembrolizumab Head and neck cancers - Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
03 Aug 2018 FDA Approves Iobenguane I 131 for Pheochromocytoma or Paraganglioma Endocrine and neuroendocrine tumours
02 Aug 2018 Testicular Cancer Survivors Have Increased Risk of Developing Subsequent Malignant Neoplasms in the Platinum Era Genitourinary cancers
31 Jul 2018 EMA Recommends Granting Marketing Authorisations for Encorafenib and Binimetinib Melanoma and other skin tumours - Personalised medicine - Anticancer agents & Biologic therapy
30 Jul 2018 EMA Recommends Granting a Marketing Authorisation for Abemaciclib Breast cancer - Anticancer agents & Biologic therapy
27 Jul 2018 EMA Recommends Granting a Marketing Authorisation for Durvalumab for the Treatment of Locally Advanced, Unresectable NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
26 Jul 2018 NICE Issues Technology Appraisal Guidance on Crizotinib for Treating ROS1-positive Advanced NSCLC Lung and other thoracic tumours - Personalised medicine - Anticancer agents & Biologic therapy